

17 June 2016

Deltex Medical Group plc
("Deltex Medical" or "the Company")

Director/PDMR Shareholding

Deltex Medical Group announces that it received notification on 16 June 2016 that its Chief Executive, Ewan Phillips, on 16 June 2016 transferred 350,000 Ordinary Shares into his Self Invested Personal Pension at a price of 4.5p per share. Ewan Phillips is the principal beneficiary of this fund and following this transaction his beneficial interest remains the same at 2,645,189 Ordinary Shares in the Company representing 0.96% of the total issued ordinary share capital of the Company.

For further information, please contact:-

Deltex Medical Group plc 01243 774 837
investorinfo@deltexmedical.com

Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Jonathan Shaw, Group Finance Director
Barry Curtis, Company Secretary

Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Chris Hardie

Financial Public Relations
IFC Advisory 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex Medical has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 650,000 patients have been treated to date using Deltex Medical's single patient disposable probes.